Phreesia beats revenue expectations in Q4, anticipates full-year revenue close to estimates

From StockStory: 2025-03-12 16:40:36

Phreesia (NYSE:PHR) exceeded revenue expectations in Q4 CY2024, with sales up 15.4% year on year to $109.7 million. The company anticipates full-year revenue around $477 million, close to analysts’ estimates. Is now the time to buy Phreesia? Phreesia’s Q4 highlights include beating analyst estimates for revenue, EPS, and adjusted EBITDA. Management forecasts revenue of $477 million and EBITDA of $83 million for FY2026. The company’s customer base grew to 4,341, with year-on-year revenue growth at 15.4%. Operating margin improved to -6.9%, up from -31.1% in the same quarter last year.

Phreesia, founded in 2005, offers a cloud-based platform for patient intake management in the healthcare technology sector. The industry focuses on software, data analytics, and workflow solutions for hospitals and clinics. Phreesia’s 27.5% annualized revenue growth over the last five years is exceptional, with recent revenue growth at 15.4% in Q4. The company’s operating margin improved by 49 percentage points over two years. While Phreesia’s EPS remains negative, it improved by 42% annually over the last five years. Analysts forecast Phreesia to break even in the next 12 months.



Read more at StockStory: Phreesia (NYSE:PHR) Posts Better-Than-Expected Sales In Q4 But Stock Drops